Drug development for neurodegenerative diseases such as Alzheimer disease (AD) is a challenge not only due to the cellular molecular mechanisms involved but also because the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). To overcome these drawbacks, a promising approach is the development of fluorinated molecules and supramolecular assemblies.
Abstract
Drug development for neurodegenerative diseases such as Alzheimer disease (AD) is a challenge not only due to the cellular molecular mechanisms involved but also because the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). To overcome these drawbacks, a promising approach is the development of fluorinated molecules and supramolecular assemblies.
This review focus on the therapeutic potential of new fluorinated molecules developed as active and selective agents for AD to achieve the desired properties in terms of pharmacokinetic/pharmacodynamics and BBB targeting. The methods to fluorinate organic molecules are described and a brief characterization of the mechanisms of AD progression and therapeutic approaches are also addressed.
The paradigm of cell biology knowledge and fluorine biochemistry is highlighted, such as organofluorine inhibitors of
Introduction
Alzheimer's disease (AD) affects more than 35 million people and it is considered the most common form of dementia worldwide. In the United States, the estimates suggest that at every 72 seconds an individual develops AD. In 30 years, this rate probably will increase to one person developing the disease every 33 seconds and the number of people worldwide with the disease is probable to triple by the year of 2050, evidence that this disease is a serious public health problem [1] .
The initial symptoms of AD are practically imperceptible and characteristically involve lapses of memory for recent events [2] . In addition, the performance for complex tasks and ability to acquire new information can be reduced [3] . Commonly an emotional control loss is observed in patients with AD, a symptom that may be accompanied by physical or verbal aggression. Over the time, the disease causes a progressive decline of the patient life with intense memory and cognition losses, leading to the immobility of the patients that succumb to respiratory difficulties. Normally, this disorder appears among people over the age of 65 years, with an average of eight year living after the appearance of the first symptoms [4] .
Due to the impact of AD on the health care systems and also on the 
The AD disease mechanism
Two pathophysiological hallmarks in the brain characterize this neuropathological disease: intracellular neurofibrillar tangles of hyperphosphorylated tau protein and extracellular accumulation of Aβ peptide (senile plaques) [3, 17, 18] . The peptide is aggregated as amyloid fibrils within the neuritic plaques and vascular deposits [19] [20] [21] [22] [23] [24] [25] . It is generally believed that Aβ precedes tau in the pathogenesis,
i.e., Aβ causes the tau pathology [26] .
The most abundant forms of Aβ peptide have 40 (~90%) and 42 (~10%) amino acids. From genetic and animal models, scientists have established a causative role of Aβ in AD [27, 28] . Several evidences indicate that the deposits maybe precede and induce the neuronal atrophy [6, 7, 29] .
Nowadays it is believed that the degree of dementia of patients are associated with the concentration of soluble aggregates of the Aβ peptide [3, 17, 30] . The Aβ peptide derivesfrom the amyloid precursor 
Figure 1 -Amyloid cascade hypothesis
The sequence of 40 residues is normally produced more abundantly by cells (concentration of secreted Aβ42 is 10-fold lower that of Aβ40) and its aggregation kinetic rate is much lower than that of the 42 (Aβ40 at 20 µM is stable for 8 days or more whereas Aβ42 aggregates immediately) [46, 47] . Aβ42 is the most fibrillogenic sequence and is thus associated with disease states. The ratio Aβ42/Aβ40 has been related to the progression of AD as its increase is associated to the aggregation of Aβ42 and consequently neurotoxicity [36] . The aggregation process of the Aβ peptide conducts to the insoluble fibrils formation, that accumulate in senile plaques, deposits that characterize AD [48, 49] . In this state Aβ is in a β-sheet conformation. The smaller aggregated intermediates are considered one of the more toxic species [3] . This species are called Aβ oligomers.
The oligomer process is very fast and is affected by many variables such as pH and temperature making the control of this process very difficult to achieve [50, 51] .
This aggregation process has a nucleation-dependent mechanism in which partially folded forms of the peptide associate to form a stable nucleus [52, 53] . This nucleus acts as a template to sequester other intermediates to add to the growing thread of aggregated peptide forming the protofibrils. The consecutive addition of partially folded intermediates to the ends of the chain leads to the formation of highly structured and insoluble amyloid fibrils. The time course of the conversion of the peptide into fibrils typically includes three phases: lag phase, elongation phase and plateau phase. In the first phase, the lag phase, the unfolding of Aβ and the formation of oligomers occur, which include β-sheet-rich species that act as nuclei for the formation of mature fibrils. In the elongation phase, once a nucleus is formed, the fibril growth is thought to proceed by the exponentially addition of monomers or oligomers to the growing nucleus. In the last phase, the plateau phase, the maximum fibril growth is reached ( Figure 2 ). Pharmacological intervention by inhibiting the function of the γ-secretase and β-secretase with a small molecule, and thus reducing Aβ levels, has been and remains a possible strategy. Though for AD treatment, the γ-secretase inhibition is an smart strategy, it has led to undesirable adverse events in clinical trials, such as notably gastrointestinal toxicity [62, 63] . These side effects are associated with blocking the processing of Notch, which are a transmembrane receptor signaling protein and also a γ-secretase substrate [64] . The modulation of γ-secretase is a possible strategy to avoid Notchrelated toxicity. To selectively inhibit the production of Aβ42 while not affecting the production of Aβ40 or Notch processing, certain nonsteroidal anti-inflammatory drugs (NSAIDs) were created [64] [65] [66] [67] [68] [69] (figure 3). Regarding to β-secretase, BACE1 is a prime drug target for inhibiting the production of Aβ. BACE1 is an aspartic protease organized into an extracellular domain with signal peptide, composed by 501 amino acids length, prodomain and catalytic domain, a transmembrane domain and a short cytoplasmic stretch of 22 amino acids. Its principal cleavage site in the APP extracellular domain forms the N-terminus of Aβ (position D672 of the longest APP isotype) [71] . The lack of Aβ generation in the brains of BACE1 deficient mice suggests that the therapeutic inhibition of BACE1 should reduce brain Aβ levels in humans for the treatment of AD. Additionally, BACE1 inhibitors may not be associated with mechanism-based toxicity [72] .
Another attractive strategy to combat the AD is the use of therapeutic peptides (linear molecules with two or more a.a. residues, but less than 100) because of their high biological activity associated with low toxicity and high specificity [73] . 
a. Fluorine properties
As predictable from its place on the periodic 
. This transformation leads to a more active compound [97] . Besides the alterations referred above, fluorine can also influence the interactions between a substrate and enzyme active sites, ligand receptor binding, translocation of molecules through biological membranes, and perturb other important biological properties [97] .
d. Fluorine incorporation methods
Fluorine incorporation in a chemical structure can be accomplished by either electrophilic or nucleophilic attack, or the most frequently used method that involves a fluoro alkyl chain addition to the core structure of the drug [101, 102] .
The substitution of H atoms with F atoms is different according to the charges of these two species. The formation of F + , specie that does not exist under normal conditions, is energetically unfavorable.
So, if the loss of a proton is required in an enzyme-catalyzed reaction, the substitution of fluorine in the hydrogen position effectively inhibit this process [97] . interaction between C-F bond and the side-chain amides of glutamine (Gln15) and asparagine (Asn27) residues are geometric preferable [149] .
Consequently, the fluorinated NPs can interact with two patches of hydrophobic residues responsible for oligomerization (Leu17-Ala21 and Ala30-Ala42). Also they can be able to interact with residues in their vicinity by exploiting the same intermolecular interaction as in Aβ assembly and disrupting the potential for further aggregation [148] .
Thus, fluorinated compounds might have a good bioavailability and influence the development of AD, including molecules, surfaces or even nanoparticles. The follow table can resume the several examples already described. 
Concluding remarks
Fluorine plays an important role in the diagnosis of many CNS diseases, including neurodegenerative disorders such as Alzheimer's disease.
The incorporation of a fluorine atom into a compound modifies its physicochemical properties. The alteration can increase the binding affinity to a specific compound, can increase metabolic stability or even affect other administration, distribution, metabolism and excretion (ADME) properties.
The demands to develop new methods for introduction of fluorine into organic molecules have led to many simple and convenient procedures.
This has increased the availability of fluorinated analogues such as biological evaluation. Even with the advances on this field, the role of fluorine in drug development and design continues capable to expand.
In this review, the attempt has been made to highlight the different fluorinated molecules already designed and synthesized and able to inhibit the β-amyloid peptide aggregation.
With this work we can expect that investigations using fluorinated compounds in the treatment of CNS disorders will continue to unabated.
Potency, selectivity and bioavailability are crucial parameters to determine the utility of these compounds in AD. 
